tbuckley/cabot-search huggingface dataset:
Abstract 10846: Gender Differences in Outcomes of Mitraclip: A Meta-Analysis
Authors: Gaurav Aggarwal, Abhishek Thandra, Kesavan Sankaramangalam, Sakshi Bansal, Venkata Alla
Journal: Circulation (2021)

Introduction: With the approval of transcatheter mitral valve edge-edge repair (TEER) for secondary mitral regurgitation, there has been a significant increase in the volume of TEER. Prior investigators have explored gender differences in outcomes of Mitraclip (the only approved TEER) with mixed results. In this study, we systematically reviewed impact of gender on Mitraclip outcomes and performed a meta-analysis to examine short-term and long-term outcomes in women versus men. Hypothesis: Females undergoing TEER with Mitraclip will have higher mortality, major adverse events and less functional improvement compared to men. Methods: Pubmed, Google scholar, Cochrane database etc were searched through 31 May 2021 for published studies reporting outcomes with Mitraclip in women versus men. Meta-analysis was performed using comprehensive meta-analysis software using random effects model. Results: Ten studies (8 manuscripts and 2 abstracts) with total of 2924 males and 1816 females were analysed. The risk of death at discharge (p=0.71), at 30 days (p=0.32) and beyond 6-12 months (p=0.97) was similar. Acute procedural success (defined by mitral regurgitation grade ≤2 at 30 days), major adverse events at 1 month (p=0.064) and at 1 year (p= 0.98), risk of renal failure (p=0.15), stroke (p=0.71) and 1 year readmission rate (p=0.42) were all similar. Females received more blood transfusion than males (RR: 1.37, CI: 1.03-1.80, p=0.02). Prevalence of NYHA 3/4 class at 1 year post-procedure (RR: 1.36, CI: 1.19-1.56, p&lt;0.01) and MLHFQ scores (RR: 1.91, CI: 1.47-2.48, p=0.01) were higher in females compared to males. Conclusions: Females have similar early and intermediate term mortality, major adverse events and rehospitalization rates compared to men following TEER with Mitraclip. However, females have less symptoms improvement as evidenced by greater frequency of NYHA class 3/4 symptoms and higher MLHFQ scores at 6-12 months after Mitraclip implantation compared to males.
Association of Adiposity With Mortality Among Black Patients With Breast Cancer
Authors: Zhiyong Guo, Jiannan Liu, Chenping Zhang
Journal: JAMA Oncology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
WHO, Global Health Workers Demand Urgent Action on Climate Change
Authors: Bridget M. Kuehn
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cardiogenic Shock After Acute Myocardial Infarction
Authors: Marc D. Samsky, David A. Morrow, Alastair G. Proudfoot, Judith S. Hochman, Holger Thiele, Sunil V. Rao
Journal: JAMA (2021)

<h3>Importance</h3> Cardiogenic shock affects between 40 000 and 50 000 people in the US per year and is the leading cause of in-hospital mortality following acute myocardial infarction. <h3>Observations</h3> Thirty-day mortality for patients with cardiogenic shock due to myocardial infarction is approximately 40%, and 1-year mortality approaches 50%. Immediate revascularization of the infarct-related coronary artery remains the only treatment for cardiogenic shock associated with acute myocardial infarction supported by randomized clinical trials. The Percutaneous Coronary Intervention Strategies with Acute Myocardial Infarction and Cardiogenic Shock (CULPRIT-SHOCK) clinical trial demonstrated a reduction in the primary outcome of 30-day death or kidney replacement therapy; 158 of 344 patients (45.9%) in the culprit lesion revascularization–only group compared with 189 of 341 patients (55.4%) in the multivessel percutaneous coronary intervention group (relative risk, 0.83 [95% CI, 0.71-0.96];<i>P</i> = .01). Despite a lack of randomized trials demonstrating benefit, percutaneous mechanical circulatory support devices are frequently used to manage cardiogenic shock following acute myocardial infarction. <h3>Conclusions and Relevance</h3> Cardiogenic shock occurs in up to 10% of patients immediately following acute myocardial infarction and is associated with mortality rates of nearly 40% at 30 days and 50% at 1 year. Current evidence and clinical practice guidelines support immediate revascularization of the infarct-related coronary artery as the primary therapy for cardiogenic shock following acute myocardial infarction.
Custom High Throughput Drug Sensitivity Assay Reveals Therapeutic Options for Chronic Myeloid Leukemia Patients Resistant to or Intolerant of Tyrosine Kinase Inhibitors
Authors: Vivian G. Oehler, Sylvia Chien, Jin Dai, Carrie L. Cummings, James Annis, Timothy J Martins, Pamela S. Becker
Journal: Blood (2021)
Abstract 12419: Internalized Weight Stigma Linked to Greater Visceral Adiposity for Women, but Not Men
Authors: Natalie G Keirns, Bryant H Keirns, Christina Sciarrillo, Sam Emerson, Misty A Hawkins
Journal: Circulation (2021)

Introduction: As visceral adipose tissue (VAT) is an important predictor of CVD risk, it is necessary to understand psychosocial factors possibly related to VAT accrual. Weight stigma is a chronic stressor which particularly impacts women and is associated with increased cortisol secretion. Given that chronically elevated cortisol is linked to VAT increase, weight stigma may lead to accumulation of visceral fat. This study investigated relationships between internalized weight stigma (IWS), VAT, and gender. Hypothesis: We hypothesized that IWS would be positively associated with VAT, and that this relationship would be moderated by gender. We predicted that the relationship between IWS and VAT would be stronger for women than for men. Methods: Participants ( N =70, 81% white, 53% women, M age =30.4±7.8 years, M BMI =28.7±5.5 kg/m 2 , M BF% =32.4±8.9%) completed in-lab measures of demographic factors (age, gender, race/ethnicity), IWS (Weight Bias Internalization Scale-Modified; WBIS-M) and visceral adiposity. VAT mass (g) was measured via DXA scan (Hologic Horizon A DXA system). Primary moderation analysis investigated the effect of gender on associations between IWS and VAT mass. Covariates were age, race/ethnicity, and total BF%. Results: Participants represented a broad range of total BF% (15-48%) and BMI (19.6-45.2 kg/m 2 ). Women displayed greater WBIS-M scores ( M =3.5, SE =0.2) than men ( M =2.7, SE =0.2; p &lt;.01). Differences between VAT mass (g) for women ( M =429.4, SE =39.7) and men ( M =480.1, SE =30.5) were non-significant ( p =.32). After adjusting for covariates in the primary moderation analysis, WBIS-M scores displayed a positive association with VAT mass ( b =31.5, p =.03). The relationship between WBIS-M scores and VAT mass was moderated by gender ( b =74.7, p =.01); no relationship between WBIS-M scores and VAT mass was observed in men ( b =-8.0, p =.68), whereas a positive association between WBIS-M scores and VAT mass was observed in women ( b =66.7, p &lt;.01). Conclusions: Internalization of weight stigma was associated with greater visceral adiposity in women across the BMI spectrum, implicating it as a chronic stressor. Future studies should investigate directionality and causality of this relationship to mitigate stigma-associated CVD risk.
Self-assembling, pH-responsive nanoflowers for inhibiting PAD4 and neutrophil extracellular trap formation and improving the tumor immune microenvironment
Authors: Di Zhu, Yu Lu, Lin Gui, Wenjing Wang, Xi Hu, Su Chen, Yanming Wang, Yuji Wang
Journal: Acta Pharmaceutica Sinica B (2021)

Self-assembling carrier-free nanodrugs are attractive agents because they accumulate at tumor by an enhanced permeability and retention (EPR) effect without introduction of inactive substances, and some nanodrugs can alter the immune environment. We synthesized a peptidyl arginine deiminase 4 (PAD4) molecular inhibitor, ZD-E-1M. It could self-assembled into nanodrug ZD-E-1. Using confocal laser scanning microscopy, we observed its cellular colocalization, PAD4 activity and neutrophil extracellular traps (NETs) formation. The populations of immune cells and expression of immune-related proteins were determined by single-cell mass cytometry. ZD-E-1 formed nanoflowers in an acidic environment, whereas it formed nanospheres at pH 7.4. Accumulation of ZD-E-1 at tumor was pH-responsive because of its pH-dependent differences in the size and shape. It could enter the nucleus and bind to PAD4 to prolong the intracellular retention time. In mice, ZD-E-1 inhibited tumor growth and metastasis by inhibiting PAD4 activity and NETs formation. Besides, ZD-E-1 could regulate the ratio of immune cells in LLC tumor-bearing mice. Immunosuppressive proteins like LAG3 were suppressed, while IFN-γ and TNF-α as stimulators of tumor immune response were upregulated. Overall, ZD-E-1 is a self-assembling carrier-free nanodrug that responds to pH, inhibits PAD4 activity, blocks neutrophil extracellular traps formation, and improves the tumor immune microenvironment.
Treatment outcomes and prognostic factors of patients with adult Langerhans cell histiocytosis
Authors: Xin‐xin Cao, Ming‐hui Duan, Ai‐lin Zhao, Hao Cai, Jia Chen, Xue‐min Gao, Ting Liu, Hua‐cong Cai, Lu Zhang, Jian Sun, Zhi‐yong Liang, Dao‐bin Zhou, Jian Li
Journal: American Journal of Hematology (2021)

Adult Langerhans cell histiocytosis (LCH) remains poorly defined. We retrospectively studied 266 newly diagnosed LCH patients to understand the clinical presentation, treatment, and prognosis of adult LCH. The median age at diagnosis was 32 years (range, 18-79 years). At the time of diagnosis, 40 patients had single lesions within a single system, 18 patients had single pulmonary LCH, 26 patients had multiple lesions within a single system (SS-m), and 182 patients had multisystem disease (MS). The most common organ involved in MS patients was the bone (69.8%), followed by the pituitary (61.5%) and lung (61.0%). BRAFV600E , BRAF deletion, and MAP2K1 mutation were detected in 38.8%, 25.4%, and 19.4% patients, respectively. BRAF deletion was found more common in patients with MS LCH compared to single-system LCH (38.5% vs 7.1%, p = .004), also in patients with liver involvement (69.2% vs 14.3%, p < .001). The estimated 3-year overall survival (OS) and event-free survival (EFS) rates were 94.4% and 54.7%, respectively, in SS-m and MS LCH. Multivariate Cox regression showed that involvement of the liver or spleen at baseline predicted poor EFS and receiving cytarabine-based therapy as a first-line treatment and age older than 30 years at diagnosis predicted favorable EFS. The involvement of risk organs and age older than 50 years predicted poor OS, and receiving cytarabine-based therapy predicted favorable OS. Therefore, BRAF deletion was correlated with MS LCH, particularly those with liver involvement. Liver or spleen involvement at baseline indicates a poor prognosis, and a cytarabine-based regimen could be considered as first-line treatment for adult LCH patients.
Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial
Authors: Hartmut Goldschmidt, Elias K Mai, Eva Nievergall, Roland Fenk, Uta Bertsch, Diana Tichy, Britta Besemer, Jan Dürig, Roland Schroers, Ivana v. Metzler, Mathias Haenel, Christoph Mann, Anne-Marie Asemissen, Bernhard Heilmeier, Stefanie Huhn, Katharina Kriegsmann, Niels Weinhold, Steffen P. Luntz, Tobias A. W. Holderried, Karolin Trautmann-Grill, Deniz Gezer, Maika Klaiber-Hakimi, Martin Mueller, Cyrus Khandanpour, Wolfgang Knauf, Markus Munder, Thomas Geer, Hendrik Riesenberg, Joerg Thomalla, Martin Hoffmann, Marc-Steffen Raab, Hans Salwender, Katja Weisel
Journal: Blood (2021)
TWEAK functions with TNF and IL-17 on keratinocytes and is a potential target for psoriasis therapy
Authors: Rinkesh K. Gupta, Donald T. Gracias, Daniela Salgado Figueroa, Haruka Miki, Jacqueline Miller, Kai Fung, Ferhat Ay, Linda Burkly, Michael Croft
Journal: Science Immunology (2021)

TWEAK synergizes with TNF and IL-17 in keratinocytes to drive psoriasis-like skin inflammation.
Abstract 10013: PRDs Are Multifunctional Oral Inhibitors of PCSK9 and ACAT2
Authors: Parini Paolo, Osman Ahmed, Matteo Pedrelli, Taichi Oshiro, Camilla Pramfalk, Mats Eriksson, Erika Mejia
Journal: Circulation (2021)

Introduction and Hypothesis: PCSK9-inhibition reduces the residual cardiovascular risk associated with LDL-cholesterol (LDL-C), but the wide-spread use of the antibody-based therapies is affected by the costs, especially in low- and middle-income countries. Hence, there is a need to identify affordable and effective drugs to inhibit PCSK9. Methods: Female and male C57BL/6J mice were fed a high fat diet prior to and during eight weeks of oral treatment with PRD125 (10 mpk/day), a molecule originally developed as a selective inhibitor of ACAT2. Also, HepG2 cells were incubated with PRD125 or PRD017 (1 and 10 μg/mL) in the presence or absence of atorvastatin (5 μmol/L). Results: PRD125 significantly reduced serum concentrations of LDL-C (-30% to -50%) and PCSK9 (&gt;-60%), without significantly affecting PCSK9 mRNA levels. Additionally, significant decreases in fasting glucose (-17%) and HOMA-IR (-50%) were also observed. As the effects by PRD125 on serum concentrations of PCSK9 were posttranscriptional, we studied whether PRD125 or PRD017 may exert similar effects in human hepatocyte-like HepG2 cells. While atorvastatin significantly increased cellular PCSK9 protein levels (~40%), significant decreased levels (~40%) were observed by PRD125 or PRD017, regardless of the presence or absence of atorvastatin. Contrary to atorvastatin, and in line with the observation in mice, PRD125 and PRD017 did not affect PCSK9 mRNA levels. Conclusion: PRD125 and PRD017 are non-species-specific posttranscriptional inhibitors of PCSK9, that exert their functions in the presence or absence of cholesterol synthesis inhibition by atorvastatin. As PRD125 also improves glucose tolerance and decreases atherosclerosis in mice by inhibiting ACAT2, PRD125 can be considered as a progenitor of a new group of multifunctional orally active molecules with great potential for treatment and prevention of atherosclerosis and cardiometabolic diseases.
Prognostic Value of Elafin in Acute Graft-Versus-Host Disease
Authors: Makda Getachew Zewde, George Morales, Isha Gandhi, Umut Ozbek, Paibel Aguayo-Hiraldo, Francis A. Ayuk, Janna Baez, Chantiya Chanswangphuwana, Hannah Choe, Zachariah DeFilipp, Aaron Etra, Stephan A. Grupp, Elizabeth O. Hexner, William J Hogan, Rebeka Javorniczky, Stelios Kasikis, Carrie Lynn Kitko, Steven Kowalyk, Elisabeth Meedt, Pietro Merli, Ryotaro Nakamura, Muna Qayed, Ran Reshef, Wolf Roesler, Tal Schechter-Finkelstein, Daniela Weber, Matthias Wölfl, Gregory A Yanik, Rachel Young, John E. Levine, James L. Ferrara, Yi-Bin Chen
Journal: Blood (2021)
Clinical, pathological, and molecular features of myelodysplasia cutis
Authors: Jérémie Delaleu, Rathana Kim, Lin-Pierre Zhao, Adèle de Masson, Marie-Dominique Vignon-Pennamen, Charles Cassius, Caroline Ram-Wolff, Martine Bagot, Emmanuelle Clappier, Lionel Adès, Marie Sebert, Jean-David Bouaziz, Pierre Fenaux, Maxime Battistella
Journal: Blood (2021)
Hydrogen Sulfide: An Emerging Precision Strategy for Gas Therapy
Authors: He Ding, Jinhu Chang, Fei He, Shili Gai, Piaoping Yang
Journal: Advanced Healthcare Materials (2021)

Advances in nanotechnology have enabled the rapid development of stimuli-responsive therapeutic nanomaterials for precision gas therapy. Hydrogen sulfide (H2 S) is a significant gaseous signaling molecule with intrinsic biochemical properties, which exerts its various physiological effects under both normal and pathological conditions. Various nanomaterials with H2 S-responsive properties, as new-generation therapeutic agents, are explored to guide therapeutic behaviors in biological milieu. The cross disciplinary of H2 S is an emerging scientific hotspot that studies the chemical properties, biological mechanisms, and therapeutic effects of H2 S. This review summarizes the state-of-art research on H2 S-related nanomedicines. In particular, recent advances in H2 S therapeutics for cancer, such as H2 S-mediated gas therapy and H2 S-related synergistic therapies (combined with chemotherapy, photodynamic therapy, photothermal therapy, and chemodynamic therapy) are highlighted. Versatile imaging techniques for real-time monitoring H2 S during biological diagnosis are reviewed. Finally, the biosafety issues, current challenges, and potential possibilities in the evolution of H2 S-based therapy that facilitate clinical translation to patients are discussed.
Association of the Frequency of In-Home Care Services Utilization and the Probability of In-Home Death
Authors: Kazuhiro Abe, Ichiro Kawachi, Taeko Watanabe, Nanako Tamiya
Journal: JAMA Network Open (2021)

<h3>Importance</h3> The provision of end-of-life care is an important policy issue associated with population aging around the world. Yet it is unclear whether the provision of in-home care services can allow patients the option of in-home death at end of life. <h3>Objective</h3> To assess whether the frequent use of in-home care services can assist recipients to stay at home at the end of life. <h3>Design, Setting, and Participants</h3> This cohort study of older adults in Japan's long-term care insurance system used national claims data. Participants were long-term care insurance beneficiaries aged 65 years or over who died in 2015, excluding those who died due to external causes such as accidents. Data analyses were conducted from October to December 2020. <h3>Exposures</h3> Mean days of in-home care service used per week from the first day of the month before the month of death to the date of death. <h3>Main Outcomes and Measures</h3> Primary outcome was whether the older person died at home (or not). To address lack of information on individual preference for place of death, we used an instrumental variable estimation with the full-time equivalent number of care workers providing in-home care services per older population at the municipality level in 2014. <h3>Results</h3> Of the 572 059 decedents included in the study, 314 743 (55.0%) were women (median [IQR] age, 87 [81-91] years). The proportion of in-home deaths was 10.5% (60 175 decedents), and 81 675 decedents (14.3%) used in-home care services at least once prior to their death. Ordinary least squares and 2-stage least squares analyses both indicated that more frequent use of in-home care was associated with a higher probability of in-home deaths (ordinary least squares estimate, 5.0 percentage points; 95% CI, 4.9-5.1 points vs 2-stage least squares estimate, 3.6 percentage points; 95% CI, 2.3-4.9 points). <h3>Conclusions and Relevance</h3> This retrospective cohort study using an instrumental variable approach demonstrated that more frequent use of in-home care services at the end of life was associated with a higher probability of in-home death. One policy implication of these results is that in order to meet the end-of-life preferences of patients, it is not only necessary to promote the provision of medical services at home but also to ensure an adequate supply of care workers.